Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Recurrent Medulloblastoma
Interventions
DRUG

Apatinib Combined With Temozolomide and Etoposide Capsules

"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."

Trial Locations (1)

Unknown

RECRUITING

Beijing Sanbo Brain Hospital, Beijing

All Listed Sponsors
lead

Beijing Sanbo Brain Hospital

OTHER